Advertisement
In its plan to establish a solid position in the international biotech market, Hiru Corporation assists MindUp Bioresearch to renew its International and US patent. Originally acquired in 1997 (International) and 1999 (USA), the patent involves the company's development of non-resistant lung and melanoma cancer treatment through the control of the gene expression on the cancer cells' cellular surface. Treatment has the ability to reduce cellular mutation in lung cancer by more than 50%.
Advertisement
MindUp Bioresearch intends to capitalize on its discoveries through Hiru Corporation and the patent renewal represents the first step in this direction. The patent renewal will secure HIRU's advantage in the further research and development of this lung and melanoma cancer treatment approach, as well as the exclusive right to market this approach internationally.
Dr. Sabera Ruzdijic, the project and team manager of the MindUp Bioresearch said, "The Hiru management sees a great potential in our cancer research for the company as a whole and shows a great interest in our advances. They offered MindUp Bioresearch extended support in all our activities, starting with this patent renewal. We have not established a clear marketing plan for this treatment approach yet, but we intend to bring our research success to the commercial level soon."
To be included in HIRU's email database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hiru Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hiru Corporation cautions you that any forward-looking information provided by or on behalf of Hiru Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hiru Corporation's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hiru Corporation's control. In addition to those discussed in Hiru Corporation's press releases, public filings, and statements by Hiru Corporation's management, including, but not limited to, Hiru Corporation's estimate of the sufficiency of its existing capital resources, Hiru Corporation's ability to raise additional capital to fund future operations, Hiru Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hiru Corporation's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hiru Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, http://www.minamargroup.net/ (IR); For (M&A) and Corporate Matters, http://www.minamargroup.com
SOURCE Hiru Corporation
